Trevi Therapeutics (NASDAQ:TRVI) Issues Earnings Results

Trevi Therapeutics (NASDAQ:TRVI) posted its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01, Zacks reports.

Trevi Therapeutics Trading Up 0.8 %

Trevi Therapeutics stock traded up $0.06 during mid-day trading on Tuesday, hitting $6.60. The company had a trading volume of 2,202,888 shares, compared to its average volume of 968,847. The company has a market capitalization of $506.93 million, a price-to-earnings ratio of -14.99 and a beta of 0.90. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39. The company’s fifty day moving average is $4.39 and its 200-day moving average is $3.66.

Insider Activity

In related news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 24.37% of the company’s stock.

Wall Street Analyst Weigh In

TRVI has been the subject of a number of research analyst reports. Oppenheimer lifted their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright boosted their target price on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a report on Monday, March 10th. Needham & Company LLC increased their target price on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 10th. D. Boral Capital restated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Friday, March 7th. Finally, Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.94.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.